 |
 |
 |
Journal articles
Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations
J Langrand-Escure
R de Crevoisier
1
C Llagostera
2
G Créhange
3
G Delaroche
C Lafond
1
C Bonin
4
F Bideault
5
P Sargos
6
S Belhomme
6
D Pasquier
7
I Latorzeff
S Supiot
2
C Hennequin
S Supiot 2
Author
C Hennequin
Author
1
LTSI - Laboratoire Traitement du Signal et de l'Image (Campus Universitaire de Beaulieu - Bât 22 - 35042 Rennes - France)
- UR1 - Université de Rennes 1 (2 rue du Thabor - CS 46510 - 35065 Rennes cedex - France)
- UNIV-RENNES - Université de Rennes (France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1099 (101, rue de Tolbiac, 75013 Paris - France)
2
CRLCC René Gauducheau (France)
3
Département de radiothérapie (208, rue des Apothicaires - 34298 MONTPELLIER Cedex 5 - France)
- CRLCC Val d'Aurelle - Paul Lamarque (France)
4
CHU Besançon (Service de Génétique Histologie Biologie du Développement et de la Reproduction Place Saint Jacques 25000 Besançon - France)
- UFC - Université de Franche-Comté (1 rue Goudimel 25030 Besançon cedex - France)
5
UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (1 Rue du Professeur Marion, 21000 Dijon - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
6
Institut Bergonié [Bordeaux] (229, cours de l'Argonne - 33076 Bordeaux - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
7
UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (3, rue Frédéric Combemale, 59020 Lille - France)
- UNICANCER (101, rue de Tolbiac, 75654 Paris Cedex 13 - France)
- Université Lille Nord de France (COMUE) (365 bis, rue Jules Guesde BP 50458 - 59658 Villeneuve d’Ascq Cedex - France)
Abstract : Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques.
Document type :
Journal articles
Domain :
Complete list of metadatas
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01807361
Contributor : Laurent Jonchère <>
Submitted on : Monday, June 4, 2018 - 4:27:20 PM
Last modification on : Friday, January 15, 2021 - 3:33:38 AM
Contributor : Laurent Jonchère <>
Submitted on : Monday, June 4, 2018 - 4:27:20 PM
Last modification on : Friday, January 15, 2021 - 3:33:38 AM
Identifiers
- HAL Id : hal-01807361, version 1
- DOI : 10.1016/j.canrad.2017.11.004
- PUBMED : 29628205
Collections
UNIV-RENNES1 | LTSI | UNIV-FCOMTE | BERGONIE | VALDAURELLE | CGFL | LAMBRET | ICO | GAUDUCHEAU | FNCLCC | UNIV-RENNES
Citation
J Langrand-Escure, R de Crevoisier, C Llagostera, G Créhange, G Delaroche, et al.. Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations. Cancer Radiothérapie, Elsevier Masson, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩. ⟨hal-01807361⟩
Metrics
Record views